# Continuing Access to Axitinib (A406- AG- 013736 ) For Patients Previously Receiving AG 013736 In Clinical Trials

> **NCT00828919** · NA · COMPLETED · sponsor: **Pfizer** · enrollment: 52 (actual)

## Conditions studied

- Solid Tumors

## Interventions

- **DRUG:** axitinib
- **DRUG:** crizotinib

## Key facts

- **NCT ID:** NCT00828919
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-03-07
- **Primary completion:** 2023-08-14
- **Final completion:** 2023-08-14
- **Target enrollment:** 52 (ACTUAL)
- **Last updated:** 2024-12-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00828919

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00828919, "Continuing Access to Axitinib (A406- AG- 013736 ) For Patients Previously Receiving AG 013736 In Clinical Trials". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00828919. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*